藥明康德
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131
China
86 21 5046 1111
https://www.wuxiapptec.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工: 41,116
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Ge Li Ph.D. | Co-Founder, Chairman, President & CEO | 41.97M | 無 | 1967 |
| Dr. Minzhang Chen Ph.D. | Co-CEO & Executive Director | 10.93M | 無 | 1969 |
| Dr. Qing Yang Ph.D. | Co-CEO & Executive Director | 7.59M | 無 | 1969 |
| Dr. Edward Hu M.B.A. | Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU | 8.37M | 無 | 1962 |
| Ms. Ming Shi | Senior VP & CFO | 無 | 無 | 1974 |
| Mr. Zhaohui Zhang | COO of China, Executive VP & Executive Director | 7.05M | 無 | 1969 |
| Mr. Yuanzhou Zhang | Joint Company Secretary | 無 | 無 | 1988 |
| Mr. Ruijia Tang | IR Director | 無 | 無 | 無 |
描述
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
公司管治
截至 2024年5月1日 止，藥明康德 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：1；董事會：2；股東權利：9；現金賠償：3。
